Nocturia affects Millions in the U.S.1

More than 50 million adults†‡

(22% of the population) experience ≥2 voids a night1,2

Nocturia (≥2 nighttime voids) affects adults of all ages

In a survey of over 9,000 adults1:

Incidence ranged from 18-43% in women aged 20 to 65+. Incidence ranged from 11-48% in men aged 20 to 65+.

Two or more nocturia episodes a night disupts sleep, since patients need to wake up frequently to void.3


Look beyond the expected
to identify the true cause of nocturia

Many believe overactive bladder (OAB) or benign prostatic hyperplasia (BPH) are responsible4

The true cause is often nocturnal polyuria (NP)

NP is found in up to 88% of patients with nocturia5

nocturnal polyuria (NP) Defined


In (NP), the kidneys produce too much urine at night6

When the volume of nighttime urine production exceeds6

of daily urine total in patients > 65

of daily urine total in patients < 65

NP often coexists with OAB and BPH

have both OAB and nocturnal polyuria7,8

>85% MEN
have both BPH and nocturnal polyuria9,11


In the treatment of nocturia, the bladder and prostate aren’t always the source of the problem

Lower Urinary Tract Symptoms (LUTS) medications may not work because they dont treat nocturnal polyuria, a disease that affects the kidneys10

Reference: 1. Vaughan CP, Fung CH, Huang AJ, et al. Differences in the association of nocturia and functional outcomes of sleep by age and gender: a cross-sectional, population-based study. Clin Ther. 2016;38(11):2386-2393. 2. Henry J Kaiser Family Foundation. residents. Accessed June 13, 2018. 3. Oelke M, De Watcher S, Drake MJ, et al. A practical approach to the management of nocturia. Int J Clin Pract. 2017;71(11):e13027:1‐11. 4. Weiss JP. Nocturia: focus on etiology and consequences. Rev Urol. 2012;14(3-4):48-55. 5. Weiss JP, van Kerrebroeck PE, Klein BM, et al. Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol. 2011;186(4):1358-1363. 6. Fine ND, Weiss JP, Wein AJ. Nocturia: consequences, classification, and management. F1000Res. 2017;6(F1000 Faculty Rev):1‐7.doi:10.12688/f1000research.11979.1:1‐7. 7. Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18(7):737-741. 8. Rovner ES, Raymond K, Andruczyk E, et al. Low-dose desmopressin and tolterodine combination therapy for treating nocturia in women with overactive bladder: a double-blind, randomized, controlled study. Low Urin Tract Symptoms. 2017. Epub:1‐11. doi:10:1111/luts.12169. 9. Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18(2):112-117. 10. Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011;108(1):6-21. 11. Yoong et al. Prevalence of Nocturnal Polyuria in Patients With Benign Prostatic Hyperplasia Med J Malaysia Vol 60 No 3 August 2005: 294-296. Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis. Eur Urol. 2012;62(5):877-890. Leslie SW, et al. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing: 2021 Jan. Last update February 14, 2021.